An InnovaTive Approach to Ventilator-Induced Diaphragmatic Dysfunction (ITAVIDD)

Antwerp University Hospital (UZA)

Status: Completed

Conditions: VIDD; Ventilator-induced Diaphragm Dysfunction

Treatments: Other: Ultrasound measurement

Study type: Observational

Funder types: Other

Identifiers

NCT02299986

B300201317057 (Other Identifier)

EC 13/12/131

Details and patient eligibility

About

'Ventilator-Induced Diaphragmatic Dysfunction (VIDD) was originally described by Vassilakopoulos and Petrof in 1998, where it is used to cover the effects of mechanical ventilation and respiratory muscle unloading on the diaphragm. A recent article by Grosu and colleagues has demonstrated that the thickness of the diaphragm decreases with about 6% a day in a small cohort of mechanically ventilated patients. This is a longitudinal, single-centre, observational cohort study to examine the long-term effects of invasive mechanical ventilation on the diaphragm, and to study the risk factors associated with VIDD.

Enrollment: 56 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient must suffer from respiratory insufficiency requiring mechanical ventilation

Exclusion criteria

• The patient has been hospitalized and mechanically ventilated (invasive or non- invasive) in the period up to 1 year before start of the study.

• The patient is known or suspected to have an anatomical malformation of the diaphragm.

• The patient suffers from a disease that may impair diaphragmatic function:

  • Central neural disease at the level of the brain (Multiple sclerosis, stroke, Arnold-Chiari malformation) and spinal cord (quadriplegia, amyotrophic lateral sclerosis, poliomyelitis, spinal muscular atrophy, syringomyelia).
  • Neural disease of the phrenic nerve (Guillain-Barré syndrome, tumor compression, neuralgic neuropathy, chronic inflammatory demyelinating polyneuropathy, Charcot-Marie-Tooth disease).
  • Disorders of the neuromuscular junction (Myasthenia gravis, Lambert- Eaton syndrome, botulism, organophosphate poisoning).
  • Muscular diseases (muscular dystrophies, myositis (infectious, inflammatory, metabolic).

• The patient is known or suspected to have a psychiatric illness inhibiting his/her cooperation with the study protocol or possibly obscuring the obtained results.

• The patient has been mechanically ventilated for over 24 hours before the first ultrasonographic measurement can be performed.

Trial design

56 participants in 1 patient group

Single arm Ultrasound measurement

Description:

Ultrasound measurement

Treatment:

Other: Ultrasound measurement